Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report

Lee, 2015, T Cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3 Le, 2018, FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome, Oncologist, 23, 943, 10.1634/theoncologist.2018-0028 Jhaveri, 2018, Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know, Clin J Am Soc Nephrol, 13, 796, 10.2215/CJN.12871117 Sun, 2018, Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies, J Immunol Res, 2018, 2386187 Hirayama, 2019, Toxicities of CD19 CAR-T cell immunotherapy, Am J Hematol, 94, S42, 10.1002/ajh.25445 Neelapu, 2018, Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148 Freyer, 2020, Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies, J Allergy Clin Immunol, 146, 940, 10.1016/j.jaci.2020.07.025 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Schuster, 2019, JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Gupta, 2020, Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma, Am J Kidney Dis, 76, 63, 10.1053/j.ajkd.2019.10.011 Gutgarts, 2020, Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery, Biol Blood Marrow Transplant, 26, 1071, 10.1016/j.bbmt.2020.02.012 Lee, 2021, Acute kidney injury after the CAR-T therapy tisagenlecleucel, Am J Kidney Dis, 77, 990, 10.1053/j.ajkd.2020.08.017 Thaunat, 2006, Nephrotic syndrome associated with hemophagocytic syndrome, Kidney Int, 69, 1892, 10.1038/sj.ki.5000352 Saleem, 2002, A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression, J Am Soc Nephrol, 13, 630, 10.1681/ASN.V133630 Frank, 2000, Dominant T cells in idiopathic nephrotic syndrome of childhood, Kidney Int, 57, 510, 10.1046/j.1523-1755.2000.00870.x Araya, 2006, A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome, Pediatr Nephrol, 21, 603, 10.1007/s00467-006-0026-5 Garin, 2000, Interleukin-8 alters glomerular heparan sulfate glycosaminoglycan chain size and charge in rats, Pediatr Nephrol, 14, 284, 10.1007/s004670050760 Tanaka, 1992, Infusion of peripheral blood mononuclear cell products from nephrotic children increases albuminuria in rats, Nephron, 60, 35, 10.1159/000186702 Yamada, 2014, Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis, CEN Case Rep, 3, 237, 10.1007/s13730-014-0127-0 De La Torre, 2011, Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis, NDT Plus, 4, 178 Fukatsu, 1993, Expression of interleukin 6 and major histocompatibility complex molecules in tubular epithelial cells of diseased human kidneys, Lab Invest, 69, 58 van Kooten, 2001, Cytokine cross-talk between tubular epithelial cells and interstitial immunocompetent cells, Curr Opin Nephrol Hypertens, 10, 55, 10.1097/00041552-200101000-00009 Kuroiwa, 2000, Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides, J Immunol, 164, 3323, 10.4049/jimmunol.164.6.3323 Wright, 2018, Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis, Am J Physiol Renal Physiol, 315, F1683, 10.1152/ajprenal.00512.2017